BACKGROUND: The effect of timing of initiation of concurrent radiation and chemotherapy after surgery on outcome of patients with glioblastoma (GBM) remains unclear. OBJECTIVE: To further explore this issue, we analyzed 4 clinical trials for patients newly diagnosed with GBM receiving concurrent and adjuvant temozolomide. METHODS: The cohort study included 198 adult patients with newly diagnosed supratentorial GBM who were enrolled from 2004 to 2010 in 4 clinical trials consisting of radiation plus temozolomide and an experimental agent. The interval to initiation of therapy was determined from the time of surgical resection. The partitioning deletion/substitution/addition algorithm was used to determine the cutoff points for timing of chemoradiation at which there was a significant difference in overall survival (OS) and progression-free survival (PFS). RESULTS: The median wait time between surgery and initiation of concurrent chemoradiation was 29.5 days (range, 7-56 days). A short delay in chemoradiation administration (at 30-34 days) was predictive of prolonged OS (hazard ratio [HR]: 0.63, P = .03) and prolonged PFS (HR: 0.68, P = .06) compared with early initiation of concurrent chemoradiation (<30 days), after adjusting for protocol and baseline prognostic variables including extent of resection by multivariate analysis. A longer delay to chemoradiation beyond 34 days was not associated with improved OS or PFS compared with early initiation (HR: 0.94, P = .77 and HR: 0.91, P = .63, respectively). CONCLUSION: A short delay in the start of concurrent chemoradiation is beyond the classic paradigm of 4 weeks post-resection and may be associated with prolonged OS and PFS.
BACKGROUND: The effect of timing of initiation of concurrent radiation and chemotherapy after surgery on outcome of patients with glioblastoma (GBM) remains unclear. OBJECTIVE: To further explore this issue, we analyzed 4 clinical trials for patients newly diagnosed with GBM receiving concurrent and adjuvant temozolomide. METHODS: The cohort study included 198 adult patients with newly diagnosed supratentorial GBM who were enrolled from 2004 to 2010 in 4 clinical trials consisting of radiation plus temozolomide and an experimental agent. The interval to initiation of therapy was determined from the time of surgical resection. The partitioning deletion/substitution/addition algorithm was used to determine the cutoff points for timing of chemoradiation at which there was a significant difference in overall survival (OS) and progression-free survival (PFS). RESULTS: The median wait time between surgery and initiation of concurrent chemoradiation was 29.5 days (range, 7-56 days). A short delay in chemoradiation administration (at 30-34 days) was predictive of prolonged OS (hazard ratio [HR]: 0.63, P = .03) and prolonged PFS (HR: 0.68, P = .06) compared with early initiation of concurrent chemoradiation (<30 days), after adjusting for protocol and baseline prognostic variables including extent of resection by multivariate analysis. A longer delay to chemoradiation beyond 34 days was not associated with improved OS or PFS compared with early initiation (HR: 0.94, P = .77 and HR: 0.91, P = .63, respectively). CONCLUSION: A short delay in the start of concurrent chemoradiation is beyond the classic paradigm of 4 weeks post-resection and may be associated with prolonged OS and PFS.
Authors: Jennifer L Clarke; Annette M Molinaro; Joanna J Phillips; Nicholas A Butowski; Susan M Chang; Arie Perry; Joseph F Costello; Ashley A DeSilva; Jane E Rabbitt; Michael D Prados Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: N Choi; M Baumann; M Flentjie; P Kellokumpu-Lehtinen; S Senan; N Zamboglou; P Kosmidis Journal: Lung Cancer Date: 2001-01 Impact factor: 5.705
Authors: P J Froud; D Mates; J S Jackson; N Phillips; S Andersen; S M Jackson; C J Bryce; I A Olivotto Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: O Vujovic; F Perera; A R Dar; L Stitt; E Yu; S M Voruganti; P T Truong Journal: Int J Radiat Oncol Biol Phys Date: 1998-03-01 Impact factor: 7.038
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Alexander L Chin; Everett J Moding; Sarah S Donaldson; Iris C Gibbs; Scott G Soltys; Susan M Hiniker; Erqi L Pollom Journal: Neuro Oncol Date: 2018-07-05 Impact factor: 12.300
Authors: Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper Journal: J Neurooncol Date: 2017-07-25 Impact factor: 4.130
Authors: Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Mark R Gilbert; Paul D Brown; Felix Bokstein; David G Brachman; Maria Werner-Wasik; Grant K Hunter; Egils Valeinis; Kirsten Hopkins; Luis Souhami; Steven P Howard; Frank S Lieberman; Dennis C Shrieve; Merideth M Wendland; Cliff G Robinson; Peixin Zhang; Benjamin W Corn Journal: Neuro Oncol Date: 2018-06-18 Impact factor: 12.300
Authors: Nasser K Yaghi; Stephanie Radu; Joseph G Nugent; David J Mazur-Hart; Brandi W Pang; Stephen G Bowden; Blair Murphy; Seunggu J Han Journal: Neurooncol Pract Date: 2022-02-02
Authors: Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp Journal: Oncology (Williston Park) Date: 2019-03-13 Impact factor: 2.990
Authors: Ruichong Ma; Aswin Chari; Paul M Brennan; Andrew Alalade; Ian Anderson; Anna Solth; Hani J Marcus; Colin Watts Journal: Neurooncol Pract Date: 2017-09-27
Authors: Domenique M J Müller; Merijn E De Swart; Hilko Ardon; Frederik Barkhof; Lorenzo Bello; Mitchel S Berger; Wim Bouwknegt; Wimar A Van den Brink; Marco Conti Nibali; Roelant S Eijgelaar; Julia Furtner; Seunggu J Han; Shawn Hervey-Jumper; Albert J S Idema; Barbara Kiesel; Alfred Kloet; Emmanuel Mandonnet; Pierre A J T Robe; Marco Rossi; Tommaso Sciortino; W Peter Vandertop; Martin Visser; Michiel Wagemakers; Georg Widhalm; Marnix G Witte; Philip C De Witt Hamer Journal: Neurooncol Adv Date: 2021-04-08